Document Format Files
| Seq | Description | Document | Type | Size |
|---|---|---|---|---|
| 1 | S-1 | tm2321853-12_s1.htm | S-1 | 3373699 |
| 2 | EXHIBIT 3.1 | tm2321853d13_ex3-1.htm | EX-3.1 | 159116 |
| 3 | EXHIBIT 3.2 | tm2321853d13_ex3-2.htm | EX-3.2 | 50301 |
| 4 | EXHIBIT 3.3 | tm2321853d13_ex3-3.htm | EX-3.3 | 128036 |
| 5 | EXHIBIT 3.4 | tm2321853d13_ex3-4.htm | EX-3.4 | 133847 |
| 6 | EXHIBIT 4.1 | tm2321853d13_ex4-1.htm | EX-4.1 | 12224 |
| 7 | EXHIBIT 4.2 | tm2321853d13_ex4-2.htm | EX-4.2 | 197497 |
| 8 | EXHIBIT 10.1 | tm2321853d13_ex10-1.htm | EX-10.1 | 75238 |
| 9 | EXHIBIT 10.2 | tm2321853d13_ex10-2.htm | EX-10.2 | 232626 |
| 10 | EXHIBIT 10.4 | tm2321853d13_ex10-4.htm | EX-10.4 | 54643 |
| 11 | EXHIBIT 10.5 | tm2321853d13_ex10-5.htm | EX-10.5 | 18697 |
| 12 | EXHIBIT 10.6 | tm2321853d13_ex10-6.htm | EX-10.6 | 31494 |
| 13 | EXHIBIT 10.7 | tm2321853d13_ex10-7.htm | EX-10.7 | 14390 |
| 14 | EXHIBIT 10.8 | tm2321853d13_ex10-8.htm | EX-10.8 | 13282 |
| 15 | EXHIBIT 10.9 | tm2321853d13_ex10-9.htm | EX-10.9 | 12829 |
| 16 | EXHIBIT 10.10 | tm2321853d13_ex10-10.htm | EX-10.10 | 12380 |
| 17 | EXHIBIT 10.11 | tm2321853d13_ex10-11.htm | EX-10.11 | 14689 |
| 18 | EXHIBIT 10.12 | tm2321853d13_ex10-12.htm | EX-10.12 | 371754 |
| 19 | EXHIBIT 10.13 | tm2321853d13_ex10-13.htm | EX-10.13 | 101970 |
| 20 | EXHIBIT 10.14 | tm2321853d13_ex10-14.htm | EX-10.14 | 358958 |
| 21 | EXHIBIT 10.15 | tm2321853d13_ex10-15.htm | EX-10.15 | 468267 |
| 22 | EXHIBIT 21.1 | tm2321853d13_ex21-1.htm | EX-21.1 | 1114 |
| 23 | EXHIBIT 23.1 | tm2321853d13_ex23-1.htm | EX-23.1 | 2089 |
| 24 | EX-FILING FEES | tm2321853d13_ex-filingfees.htm | EX-FILING FEES | 12062 |
| 25 | GRAPHIC | bc_stagedev-4c.jpg | GRAPHIC | 78548 |
| 26 | GRAPHIC | bc_treated-4clr.jpg | GRAPHIC | 86880 |
| 27 | GRAPHIC | bc_treatment-4c.jpg | GRAPHIC | 77476 |
| 28 | GRAPHIC | fc_acrylamide-4clr.jpg | GRAPHIC | 58000 |
| 29 | GRAPHIC | fc_arm-4c.jpg | GRAPHIC | 118564 |
| 30 | GRAPHIC | fc_cohort-4c.jpg | GRAPHIC | 86044 |
| 31 | GRAPHIC | fc_combination-4c.jpg | GRAPHIC | 74878 |
| 32 | GRAPHIC | fc_egfr-4c.jpg | GRAPHIC | 84119 |
| 33 | GRAPHIC | lc_baf301-4c.jpg | GRAPHIC | 36004 |
| 34 | GRAPHIC | lc_baf302-4c.jpg | GRAPHIC | 40593 |
| 35 | GRAPHIC | lc_baf303-4clr.jpg | GRAPHIC | 38742 |
| 36 | GRAPHIC | lc_baf304-4c.jpg | GRAPHIC | 42254 |
| 37 | GRAPHIC | lc_invivo01-4c.jpg | GRAPHIC | 39924 |
| 38 | GRAPHIC | lc_invivo02-4c.jpg | GRAPHIC | 38183 |
| 39 | GRAPHIC | lc_median-4clr.jpg | GRAPHIC | 68853 |
| 40 | GRAPHIC | lc_plasamconcent-4c.jpg | GRAPHIC | 56296 |
| 41 | GRAPHIC | lg_arrivent-4c.jpg | GRAPHIC | 11978 |
| 42 | GRAPHIC | pc_cancercases-4c.jpg | GRAPHIC | 52304 |
| 43 | GRAPHIC | pc_confidential-4c.jpg | GRAPHIC | 32944 |
| 44 | GRAPHIC | ph_egfr-4c.jpg | GRAPHIC | 115583 |
| 45 | GRAPHIC | tb_agents-4c.jpg | GRAPHIC | 64395 |
| 46 | GRAPHIC | tb_character-4c.jpg | GRAPHIC | 57943 |
| 47 | GRAPHIC | tb_confirmedorr-4c.jpg | GRAPHIC | 108067 |
| 48 | GRAPHIC | tb_drug-4c.jpg | GRAPHIC | 31487 |
| 49 | GRAPHIC | tb_overviewtrae-4c.jpg | GRAPHIC | 80658 |
| 50 | GRAPHIC | tb_patient-4c.jpg | GRAPHIC | 58364 |
| 51 | GRAPHIC | tb_preferred-4c.jpg | GRAPHIC | 78997 |
| 52 | GRAPHIC | tb_treatment-4c.jpg | GRAPHIC | 67254 |
| 53 | GRAPHIC | tm2321853d13_ex10-10img001.jpg | GRAPHIC | 41209 |
| 54 | GRAPHIC | tm2321853d13_ex4-1img01.jpg | GRAPHIC | 387729 |
| 55 | GRAPHIC | tm2321853d13_ex4-1img02.jpg | GRAPHIC | 210512 |
| Complete submission text file | 0001104659-24-001804.txt | 9161918 |
EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-1 | Act: 33 | File No.: 333-276397 | Film No.: 24516457
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)
